Go Pro
→ Iran War Shock: What I Was Told In That Private Meeting (From Banyan Hill Publishing) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
enVVeno Medical Corporation stock logo
NVNO
enVVeno Medical
$10.60
-0.3%		$10.69
$8.67
▼
$179.55
$7.09M1.0922,990 shs2,338 shs
PetVivo Holdings, Inc. stock logo
PETV
PetVivo
$0.69
+7.7%		$0.77
$0.60
▼
$1.69
$26.15M1.2310,960 shs17,300 shs
Predictive Oncology Inc. stock logo
POAI
Predictive Oncology
$8.38
-1.4%		$7.20
$0.71
▼
$16.54
$28.44M1.35473,545 shs203,136 shs
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
$3.87
+6.0%		$4.56
$2.90
▼
$23.42
$25.13M1.4111,679 shs96,100 shs
10 Best Stocks to Own - Summer 2026 Cover
10 Best Stocks to Own - Summer 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
enVVeno Medical Corporation stock logo
NVNO
enVVeno Medical
+0.67%+2.02%-2.12%+0.95%-93.74%
PetVivo Holdings, Inc. stock logo
PETV
PetVivo
+7.66%-4.31%-17.98%-11.67%-12.78%
Predictive Oncology Inc. stock logo
POAI
Predictive Oncology
+21.08%+15.49%+12.14%+53.99%-27.51%
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
+6.03%+1.04%-6.97%-36.45%-66.15%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
enVVeno Medical Corporation stock logo
NVNO
enVVeno Medical
$10.60
-0.3%		$10.69
$8.67
▼
$179.55
$7.09M1.0922,990 shs2,338 shs
PetVivo Holdings, Inc. stock logo
PETV
PetVivo
$0.69
+7.7%		$0.77
$0.60
▼
$1.69
$26.15M1.2310,960 shs17,300 shs
Predictive Oncology Inc. stock logo
POAI
Predictive Oncology
$8.38
-1.4%		$7.20
$0.71
▼
$16.54
$28.44M1.35473,545 shs203,136 shs
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
$3.87
+6.0%		$4.56
$2.90
▼
$23.42
$25.13M1.4111,679 shs96,100 shs
10 Best Stocks to Own - Summer 2026 Cover
10 Best Stocks to Own - Summer 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
enVVeno Medical Corporation stock logo
NVNO
enVVeno Medical
+0.67%+2.02%-2.12%+0.95%-93.74%
PetVivo Holdings, Inc. stock logo
PETV
PetVivo
+7.66%-4.31%-17.98%-11.67%-12.78%
Predictive Oncology Inc. stock logo
POAI
Predictive Oncology
+21.08%+15.49%+12.14%+53.99%-27.51%
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
+6.03%+1.04%-6.97%-36.45%-66.15%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
enVVeno Medical Corporation stock logo
NVNO
enVVeno Medical
2.33
HoldN/AN/A
PetVivo Holdings, Inc. stock logo
PETV
PetVivo
0.00
N/AN/AN/A
Predictive Oncology Inc. stock logo
POAI
Predictive Oncology
1.00
SellN/AN/A
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
2.43
Hold$56.401,357.36% Upside

Current Analyst Ratings Breakdown

Latest NVNO, PSTV, POAI, and PETV Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/17/2026
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
7/7/2026
enVVeno Medical Corporation stock logo
NVNO
enVVeno Medical
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold
7/6/2026
enVVeno Medical Corporation stock logo
NVNO
enVVeno Medical
LADENBURG THALM/SH SH logo
LADENBURG THALM/SH SH
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
6/30/2026
enVVeno Medical Corporation stock logo
NVNO
enVVeno Medical
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
6/15/2026
enVVeno Medical Corporation stock logo
NVNO
enVVeno Medical
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
6/8/2026
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
Ascendiant Capital Markets logo
Ascendiant Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$65.00 ➝ $57.00
(Data available from 8/1/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
enVVeno Medical Corporation stock logo
NVNO
enVVeno Medical
N/AN/AN/AN/A$41.38 per shareN/A
PetVivo Holdings, Inc. stock logo
PETV
PetVivo
$1.05M25.00N/AN/A($0.03) per share-22.97
Predictive Oncology Inc. stock logo
POAI
Predictive Oncology
$1.66M17.09N/AN/A($0.46) per share-18.22
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
$5.21M5.11N/AN/A$0.72 per share5.38
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
enVVeno Medical Corporation stock logo
NVNO
enVVeno Medical
-$19.47M-$25.54N/AN/AN/AN/A-58.73%-53.60%N/A
PetVivo Holdings, Inc. stock logo
PETV
PetVivo
-$10.95M-$0.38N/AN/AN/A-902.82%-4,813.07%-281.78%8/13/2026 (Estimated)
Predictive Oncology Inc. stock logo
POAI
Predictive Oncology
-$12.66M-$13.50N/AN/AN/A-5,065.23%-732.73%-235.55%N/A
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
-$22.39M-$2.30N/AN/AN/A-230.24%-198.48%-73.13%8/13/2026 (Estimated)

Latest NVNO, PSTV, POAI, and PETV Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2026N/A
PetVivo Holdings, Inc. stock logo
PETV
PetVivo
-$0.08N/AN/AN/A$0.01 millionN/A
8/13/2026Q2 2026
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
-$0.88N/AN/AN/A$1.11 millionN/A
7/30/2026Q2 2026
enVVeno Medical Corporation stock logo
NVNO
enVVeno Medical
-$4.69-$5.37-$0.68-$5.37$1.00 millionN/A
5/15/2026Q1 2026
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
-$0.8480-$1.05-$0.2020-$1.05$0.97 million$1.03 million
5/7/2026Q1 2026
enVVeno Medical Corporation stock logo
NVNO
enVVeno Medical
-$8.40-$5.89+$2.51-$5.89$0.50 millionN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
enVVeno Medical Corporation stock logo
NVNO
enVVeno Medical
N/AN/AN/AN/AN/A
PetVivo Holdings, Inc. stock logo
PETV
PetVivo
N/AN/AN/AN/AN/A
Predictive Oncology Inc. stock logo
POAI
Predictive Oncology
N/AN/AN/AN/AN/A
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
enVVeno Medical Corporation stock logo
NVNO
enVVeno Medical
N/A
11.89
11.89
PetVivo Holdings, Inc. stock logo
PETV
PetVivo
0.02
0.42
0.47
Predictive Oncology Inc. stock logo
POAI
Predictive Oncology
N/A
0.01
0.01
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
N/A
2.27
2.27

Institutional Ownership

CompanyInstitutional Ownership
enVVeno Medical Corporation stock logo
NVNO
enVVeno Medical
34.71%
PetVivo Holdings, Inc. stock logo
PETV
PetVivo
24.55%
Predictive Oncology Inc. stock logo
POAI
Predictive Oncology
9.04%
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
3.28%

Insider Ownership

CompanyInsider Ownership
enVVeno Medical Corporation stock logo
NVNO
enVVeno Medical
15.00%
PetVivo Holdings, Inc. stock logo
PETV
PetVivo
10.84%
Predictive Oncology Inc. stock logo
POAI
Predictive Oncology
1.21%
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
2.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
enVVeno Medical Corporation stock logo
NVNO
enVVeno Medical
30670,000568,000Optionable
PetVivo Holdings, Inc. stock logo
PETV
PetVivo
2037.95 million19.06 millionNot Optionable
Predictive Oncology Inc. stock logo
POAI
Predictive Oncology
303.39 million3.35 millionNot Optionable
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
206.88 million6.71 millionNot Optionable

Recent News About These Companies

Plus Therapeutics Inc.: Cerenome Launches as an Integrated CNS Oncology Company
July 31 at 1:27 PM  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-07/69184715-plus-therapeutics-inc-cerenome-launches-as-an-integrated-cns-oncology-company-399.htm
Cerenome Launches as an Integrated CNS Oncology Company
July 31 at 8:30 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/31/3336793/0/en/cerenome-launches-as-an-integrated-cns-oncology-company.html
Plus Therapeutics Announces Scientific Presentations and Sponsored Symposium at 2026 SNO/ASCO CNS Metastases Conference
July 28, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/28/3334137/0/en/plus-therapeutics-announces-scientific-presentations-and-sponsored-symposium-at-2026-sno-asco-cns-metastases-conference.html
Plus Therapeutics Inc.: Plus Therapeutics Secures Regional Coverage Agreement with Medical Mutual for CNSide Cerebrospinal Fluid Assay for Metastatic CNS Cancer
July 21, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-07/69082107-plus-therapeutics-inc-plus-therapeutics-secures-regional-coverage-agreement-with-medical-mutual-for-cnside-cerebrospinal-fluid-assay-for-metastatic-399.htm
Plus Therapeutics Secures Regional Coverage Agreement with Medical Mutual for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer
July 21, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/21/3330332/0/en/plus-therapeutics-secures-regional-coverage-agreement-with-medical-mutual-for-cnside-cerebrospinal-fluid-assay-for-metastatic-cns-cancer.html
Plus Therapeutics and Genomic Testing Cooperative Partner to Integrate Next-Generation Sequencing Into the CNSide® CSF Assay Platform
July 16, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/16/3328365/0/en/plus-therapeutics-and-genomic-testing-cooperative-partner-to-integrate-next-generation-sequencing-into-the-cnside-csf-assay-platform.html
Plus Therapeutics Highlights NCCN CNS Cancers Guidelines Update and Reinforces Clinical Role of CNSide® in Leptomeningeal Metastases Monitoring
July 14, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/14/3326729/0/en/plus-therapeutics-highlights-nccn-cns-cancers-guidelines-update-and-reinforces-clinical-role-of-cnside-in-leptomeningeal-metastases-monitoring.html
Plus Therapeutics Inc.
July 2, 2026  |  barrons.comhttps://www.barrons.com/market-data/stocks/pstv/company-people?gaa_at=eafs&gaa_n=AWEtsqcSV2x2NL1k-FvQMUTLjCm9qt-_bJJ_1_2r9FxRrNgAlW_bC1uzmtgq&gaa_sig=T1Ip-AMMiw2TMzDxXKCsR9rYhO1gZzPl_nOgdSHfFcUk0jp52cFxY590K7kKhbdwn22qO3__695j0roHw1buuw%25253D%25253D&gaa_ts=69b47cee
Plus Therapeutics to rebrand as Cerenome and adopt CNSY ticker on August 3 (PSTV)
June 30, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/plus-therapeutics-rebrand-cerenome-adopt-124948664.html
Plus Therapeutics, Inc. (PSTV) Discusses Rebranding and Integrated CNS Oncology Platform Strategy Transcript
June 30, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4918866-plus-therapeutics-inc-pstv-discusses-rebranding-and-integrated-cns-oncology-platform-strategy
Plus Therapeutics to Rebrand as Cerenome, Affirm 2026 Guidance and Report CNSide Commercial Progress
June 30, 2026  |  quiverquant.comQ
Plus Therapeutics Provides Mid-Year Business Update Including Corporate Rebranding
June 30, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/30/3319554/0/en/plus-therapeutics-provides-mid-year-business-update-including-corporate-rebranding.html
Plus Therapeutics Subsidiary CNSide Diagnostics Signs National Coverage Agreement with Elevance Health for CNSide CSF Tumor Cell Enumeration Assay
June 25, 2026  |  quiverquant.comQ
Plus Therapeutics Secures National Coverage Agreement with Elevance Health for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer
June 25, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/25/3317434/0/en/plus-therapeutics-secures-national-coverage-agreement-with-elevance-health-for-cnside-cerebrospinal-fluid-assay-for-metastatic-cns-cancer.html
Plus Therapeutics to Provide Business Update Call on June 30, 2026
June 23, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/23/3315850/0/en/plus-therapeutics-to-provide-business-update-call-on-june-30-2026.html
Plus Therapeutics Launches New At-The-Market Equity Program
June 5, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/plus-therapeutics-launches-new-at-the-market-equity-program?utm_source=marketbeat.com&utm_medium=referral
Plus Therapeutics gains CAP accreditation for CNSide CSF assay platform
June 4, 2026  |  proactiveinvestors.comhttps://www.proactiveinvestors.com/companies/news/1093474?snapi
CNSide Diagnostics, a Plus Therapeutics Subsidiary, Achieves Prestigious CAP Accreditation for Clinical Laboratory
June 4, 2026  |  quiverquant.comQ
Plus Therapeutics Announces CAP Accreditation of CNSide® Diagnostics Clinical Laboratory
June 4, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/04/3306660/0/en/plus-therapeutics-announces-cap-accreditation-of-cnside-diagnostics-clinical-laboratory.html
Plus Therapeutics Showcases CNSide's Impact on Early Diagnosis and Cost Reduction at ISPOR Annual Meeting
May 26, 2026  |  quiverquant.comQ

New MarketBeat Followers Over Time

Media Sentiment Over Time

enVVeno Medical stock logo

enVVeno Medical NASDAQ:NVNO

$10.60 -0.03 (-0.28%)
Closing price 07/31/2026 03:46 PM Eastern
Extended Trading
$10.41 -0.19 (-1.79%)
As of 07/31/2026 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

enVVeno Medical Corporation (Nasdaq: NVNO) is an medical device company focused on the development of innovative bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. The company's lead product, the VenoValve®️, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI). Deep venous CVI occurs when valves inside of the deep veins of the leg become damaged, resulting in insufficient blood being returned to the heart. The malfunctioning vein valves cause blood to flow backwards (reflux) and pool in the lower leg, increasing the pressure within the veins of the leg (venous hypertension). In the most severe cases, CVI can lead to venous ulcers (open skin sores) that become chronic and difficult to heal. The VenoValve is implanted in the femoral vein and works as a replacement venous valve, designed to reduce reflux and venous hypertension, and to restore proper directional blood flow back to the heart. With severe deep venous CVI impacting an estimated 2.4 million people in the U.S., who have no effective treatment options, the VenoValve has received Breakthrough Device Designation from the U.S. Food and Drug Administration, and is currently being evaluated in the SAVVE U.S. clinical trial.

PetVivo stock logo

PetVivo NASDAQ:PETV

$0.69 +0.05 (+7.66%)
As of 07/31/2026 03:57 PM Eastern

PetVivo Holdings, Inc., a biomedical device company, engages in the manufacturing, commercializing, and licensing of medical devices and biomaterials for the treatment of afflictions and diseases in animals. Its lead product is Spryng, a veterinarian-administered, intraarticular injection for the management of lameness and other joint afflictions, such as osteoarthritis in dogs and horses. The company's pipeline products also include therapeutic devices for veterinary and human clinical applications. PetVivo Holdings, Inc. was founded in 2009 and is headquartered in Minneapolis, Minnesota.

Predictive Oncology stock logo

Predictive Oncology NASDAQ:POAI

$8.38 -0.12 (-1.41%)
As of 07/31/2026

Predictive Oncology Inc. operates as a science-driven company on the oncology drug discovery. It provides various solutions for the oncology drug development. The company, through the integration of scientific rigor and machine learning, has developed the ability to advance molecules into medicine by introducing human diversity earlier into the discovery process with the pairing of artificial intelligence and the biobank of approximately 150K tumor samples. It operates through four segments: Helomics, zPREDICTA, Soluble, and Skyline. The Helomics segment provides services that include the application of AI, collaboration projects, and clinical testing. The zPREDICTA segment develops organ-specific disease models that provide 3D reconstruction of human tissues representing each disease state and mimicking drug response for testing of anticancer agents. The Soluble segment provides services using a self-contained automated system that conducts self-interaction chromatography screens using additives and excipients included in protein formulations resulting in soluble and physically stable formulations for biologics. This segment also offers protein stability analysis services; protein solubility kits that allow rapid identification of soluble formulations; and proprietary technologies for bacterial endotoxin detection and removal. The Skyline segment provides STREAMWAY System, a wall-mounted fully automated system, which virtually eliminates exposure to blood, irrigation fluid, and other infectious fluids found in the healthcare environment. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was incorporated in 2002 and is headquartered in Eagan, Minnesota.

Plus Therapeutics stock logo

Plus Therapeutics NASDAQ:PSTV

$3.87 +0.22 (+6.03%)
Closing price 07/31/2026 04:00 PM Eastern
Extended Trading
$3.91 +0.04 (+1.03%)
As of 07/31/2026 07:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. The company also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere that is designed to treat various solid organ cancers comprising primary and secondary liver cancers by intra-arterial injection. It has license agreements with NanoTx, Corp. and The University of Texas Health Science Center at San Antonio. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas